In 1964 Israeli chemist Raphael Mcechoulam boarded a bus to the Weitzman Institute in Rehovot with 5 kilos of hashish he received from the Israeli police. He used the material to isolate and identify THC, the psychoactive compound in cannabis. The discovery saw him crowned as “the father of cannabis research”.
Cannabinoid medicine specialist company Zelira Therapeutics (ASX: ZLD) is paying homage to the scientist by naming their new line of skincare products RAF FIVE.
The Company has just launched the product line in the US through its dermatology subsidiary Ilera Derm.
The line uses pharmaceutical-grade CBD in five products including a cleanser, acne spot treatment, moisturiser and SPF and acne treatments. The line will be Zelira’s first foray into the acne medication market worth over USD $11 billion worldwide.
Alongside acne fighting and skin loving ingredients the products also contain Zylorma, a patent-pending acne treatment developed by Zelira in partnership with cosmetic dermatologist Dr. Karyn Grossman. Zylorma contains a mix of CBD, salicylic acid and other compounds to clear bacteria and unclog pores.
Following a month of use, 45 people reported significant improvements in their skin including the improvement of blemishes, smoother, more even-toned skin and reduced incidence of blemishes. Results were noticeable after just 7 days’ use.
CEO and Managing Director of Zelira, Dr. Oludare Odumosu said: “I am excited to announce the launch of Zelira’s Dermatology subsidiary and the RAF FIVE acne treatment line of skincare products. Dr. Grossman’s reputation and experience in the cosmetic dermatology industry, combined with Zelira’s peerless position in a cannabinoid space, is the perfect combination. We have a unique opportunity to present a differentiated suite of proven acne treatment solutions to the USD$11 billion acne treatment market where there is a high level of dissatisfaction with the existing products and unmet needs. Zelira is staking a claim in the cannabinoid- based, over- the counter skin care product market with our differentiated dermatology.
Ilera Derm is working to develop more topical products which are anticipated to be launched next year.
- Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler - August 5, 2022
- Getting things from A to B isn’t as simple as it seems, until Yojee gets involved - August 4, 2022
- NASDAQ biotech stocks have taken a hit, but this little Aussie biotech is quietly confident - August 3, 2022